Davis Capital Management’s Ligand Pharmaceuticals LGND Stock Holding History

Davis Capital Management’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$316	Buy	+1	New	+$236	﹤0.01%	719

Other funds holding LGND

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Context Capital Management Lajolla, California $5.15B AUM 1.28% 1-Year Est. Return

Pembroke Management Montreal, Quebec, Canada $637M AUM 40.98% 1-Year Est. Return

Moody Aldrich Partners Marblehead, Massachusetts $557M AUM 122.79% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS)

New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return

Isthmus Partners Madison, Wisconsin $1.03B AUM 22.86% 1-Year Est. Return

Woodstock Corp Boston, Massachusetts $1.2B AUM 26.37% 1-Year Est. Return

Moody National Bank Trust Division Galveston, Texas $1.21B AUM 38.93% 1-Year Est. Return

Cookson Peirce & Co Pittsburgh, Pennsylvania $3.04B AUM 94.11% 1-Year Est. Return

Handelsbanken Fonder

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

Davis Capital Management's LGND Position: Q2 2026 in Review

Davis Capital Management opened a new position in Ligand Pharmaceuticals (LGND) in Q2 2026: 1 share worth $316. The stake represents ﹤0.01% of the portfolio and ranks #719 among its holdings.

83 funds tracked by Wall St. Rank hold LGND as of Q2 2026.

Davis Capital Management held 1 share of Ligand Pharmaceuticals worth $316 as of Q2 2026.
Ligand Pharmaceuticals was a new Davis Capital Management position in Q2 2026.
Ligand Pharmaceuticals made up ﹤0.01% of Davis Capital Management's portfolio in Q2 2026, its #719 holding.
83 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.

Based on Davis Capital Management's 13F filing for Q2 2026, filed 16 Jul 2026.